Men with coronary artery disease who used phosphodiesterase-5 (PDE-5) inhibitors for erectile dysfunction had fewer adverse cardiovascular events than those taking the prostaglandin drug alprostadil ...

Men with stable CAD who are being treated for erectile dysfunction (ED) have a lower risk of dying if their medication is a phosphodiesterase 5 (PDE5) inhibitor rather than alprostadil, observational ...

SaveHealth reports that choosing an erectile dysfunction medication involves comparing effectiveness, side effects, and costs ...

Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago. A study from ...

Men who filled prescriptions for erectile dysfunction drugs in the years following a heart attack had a substantially lower risk of dying or being hospitalized for heart failure than men who did not ...

SAN DIEGO, March 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that the Mexican Patent Office ("MPO") will grant an additional patent for ...

CMS said in a response that it agrees it should strengthen its internal controls, but said it did not concur that it should collaborate with the FDA to create and maintain a comprehensive list of such ...

Taxpayers paid more than $3.1 million in 2007 and 2008 for sexual or erectile dysfunction drugs such as Viagra that should not have been reimbursed under federal rules for Part D, according to a ...